Amino acid concentrations in maternal plasma and amniotic fluid in relation to fetal insulin secretion during the last trimester of pregnancy in gestational and type I diabetic women and women with small-for-gestational-age infants

Free amino acid concentrations were determined in maternal plasma and amniotic fluid (AF) under standardized and unstressed conditions in four groups of women comprising 6 gestational and 13 type I diabetics, 10 women with small-for-gestational-age (SGA) infants, and 18 healthy control women between 36 and 39 weeks of gestation. Plasma values for branched chain amino acids (the sum of leucine, isoleucine and valine) did not differ significantly between the four groups. The corresponding values in AF were significantly higher (P less than 0.05) in the type I diabetic group and significantly lower (P less than 0.05) in the gestational diabetic group as compared to the control group. The mean AF C-peptide concentration was elevated but not significantly so in gestational (0.69 nmol/l) or type I diabetic (0.54 nmol/l) pregnancies and significantly lower (P less than 0.05) in women with SGA infants (0.28 nmol/l) as compared to the control group (0.38 nmol/l). There was a significant correlation between C-peptide in AF and branched chain amino acids in maternal plasma (r = 0.63; P less than 0.05) as well as to maternal blood glucose (r = 0.79; P less than 0.01) in the type I diabetic group, which merely suggests a greater beta cell reactivity to insulin secretagogues in offspring of diabetic mothers. The correlation between AF C-peptide and branched chain amino acids in maternal plasma was significantly inverse in women with SGA infants (r = -0.75; P less than 0.05). Both individual, branched chain, or total amino acid concentration in AF were unrelated to AF C-peptide.     

Interrelationship between amniotic fluid C-peptide and catecholamines in the last trimester of diabetic pregnancy

Amniotic fluid concentration and content (amniotic fluid volume X concentration) of C-peptide and catecholamines (epinephrine, norepinephrine) and their interrelationship was studied in nine women with gestational diabetes, in 14 women with type I diabetes, and in 20 healthy control women between the thirty-sixth and thirty-ninth week of gestation. Mean amniotic fluid volume was significantly larger (p less than 0.05) in the type I diabetic group than in the control group. Mean concentration and content of amniotic fluid C-peptide were elevated in women with gestational diabetes, significantly so in women with type I diabetes (p less than 0.05) as compared with nondiabetic control women. Mean amniotic fluid catecholamine concentrations were lower, although not statistically so, in both insulin-dependent and gestational diabetic women than in control women. Mean amniotic fluid catecholamine content was higher, although not statistically so, in women with gestational diabetes than in control women. In the type I diabetic group, epinephrine content was significantly lower (p less than 0.05) and norepinephrine content significantly higher (p less than 0.05) than in the control group. A significant positive correlation between the content of norepinephrine and C-peptide was found in control women (r = 0.57; p less than 0.05) and in women with gestational diabetes (r = 0.75; p less than 0.05). The close interrelationship could indicate a parallel maturation of these two hormonal systems.     

Placental weight in diabetic pregnancies

The placenta from 30 women with diabetes mellitus were examined and weighed at delivery. Nineteen of these were from women with overt and eleven from women with gestational diabetes. Eleven placentae from normal pregnancies served as controls. There was no difference between the mean +/- s.d. placental weight for the diabetic group and the control group (609 +/- 148 versus 591 +/- 93 g, NS). The mean placental weight ratios for the diabetic group and the control group were also similar (0.98 +/- 0.23 versus 0.89 +/- 0.15, NS). Moreover, there was no difference between the weights and weight ratios of placentae from women with overt (622 +/- 173 g, 1.02 +/- 0.27) and those with gestational diabetes (586 +/- 90 g, versus 0.90 +/- 0.13). Placental weights correlated with birthweights (r = 0.70, P less than 0.01) and with skinfold thickness measurements fo the infants (r = 0.40, P less than 0.05), but neither with gestational ages (r = 0.15, NS) nor with maternal glycosylated haemoglobin levels in the third trimester (r = 0.24, NS). Among the women with overt diabetes, placental weights were greater in those in White's class B and C than those in class D and R (689 +/- 143 versus 530 +/- 177 g; P less than 0.05). In general, placentae from well controlled diabetic patients were not heavier than those from normal pregnant women, although there was an increase in placental weight in White's class B and C, as compared with those in class D and R.     

Amniotic fluid C-peptide and phosphatidyl glycerol in diabetic pregnancy

The concentrations of C-peptide and phosphatidylglycerol in the amniotic fluid were determined in 36 pregnant diabetic women. Twenty-one patients who were being treated with insulin for gestational diabetes as well as 15 patients who were insulin dependent were studied. All patients were subjected to a program of strict metabolic control, and amniocentesis was performed at gestational week 36-37. Phosphatidyl glycerol was present in the amniotic fluid in 15 cases and absent in 21. The mean concentration of C-peptide did not differ whether phosphatidyl glycerol was present or absent. (C-peptide: 0.56 +/- 0.06 and 0.43 +/- 0.05 nmol/l respectively). Although the mean value for amniotic fluid C-peptide in both groups was close to that in diabetic pregnancies with an uneventful neonatal outcome, it was significantly higher than that in non-diabetic pregnancies, indicating minor fetal hyperinsulinemia. The level of C-peptide in the amniotic fluid showed a correlation to the subsequent birthweight of the infant (r = 0.50; p less than 0.01). It is concluded that with rigorous metabolic control of the pregnant diabetic patient, the presence or absence of phosphatidyl glycerol, as an index of fetal lung maturity, is apparently not related to the level of C-peptide in the amniotic fluid.     

Umbilical artery velocimetry in insulin dependent diabetes mellitus (IDDM) pregnancies

Seven hundred and sixty seven Doppler umbilical artery velocity waveform analyses were performed in 108 pregnant insulin-dependent diabetes mellitus (IDDM) women. No significant correlation between mean third trimester systolic to diastolic (S/D) ratio and either mean blood glucose (r = 0.19) or glycosylated hemoglobin levels (r = 0.28) was found. Mean second and third trimester S/D ratios differed significantly in patients with or without vascular disease (P less than 0.05). Furthermore, women without vasculopathy who demonstrated an elevated S/D developed preeclampsia and delivered appropriate for gestational age infants while patients with vascular disease or chronic hypertension and elevated third trimester S/D (greater than 3) delivered intra uterine growth retarded (IUGR) infants. Moreover, in most of the latter group elevated S/D ratios were recorded in the second trimester prior to ultrasound documentation of IUGR. Our data suggest that in the absence of vasculopathy normal fetal placental resistance can be expected in most pregnancies complicated by diabetes. Patients with vasculopathy are at higher risk for fetal IUGR, which may be identified by early umbilical artery velocimetry.     

Lymphocyte subpopulations in intrauterine growth retardation in women with or without previous pregnancies

OBJECTIVE: To evaluate lymphocyte subpopulations in pregnant women with intrauterine growth retardation (IUGR). STUDY DESIGN: Forty-two normotensive and healthy women with singleton pregnancies and intrauterine growth retardation were studied in the third trimester of pregnancy and compared with 42 normal pregnant women. Peripheral blood lymphocytes were studied using murine monoclonal antibodies and flow cytometry. RESULTS: B-lymphocytes in both total number (312.54 vs. 163.19 cells/mm3; P = 0.000003) and percentage (11.04% vs. 7.07%; P = 0.000002) were significantly increased in patients with IUGR in comparison to normal pregnant women. Significant correlations were found between birthweight and both total number and percentage of lymphocytes B. In primigravid women, we found that women with IUGR had a higher total lymphocyte count (2749.09 vs. 2130 cells/mm3; P = 0.006), higher T-lymphocyte count (2053.77 vs. 1676.40 cells/mm3; P = 0.02), higher B-lymphocyte count and percentage (309.13 vs. 145.36 cells/mm3; P = 0.000001) (11.45 vs. 6.81%); P = 0.00001), higher CD4 lymphocyte count and percentage (1342.68 vs. 972.22 cells/mm3, P = 0.001) (49.18 vs. 44.04%; P = 0.04), lower CD8-lymphocytes percentage (28.27 vs. 32.9%; P = 0.04), and higher CD4/CD ratio (1.83 vs. 1.46; P = 0.02) than the normal control group. CONCLUSIONS: B-lymphocytes are increased in women with IUGR in comparison to women with normal pregnancies and there was a significant negative correlation between maternal B-lymphocytes and birthweight. With respect to T-lymphocytes, the immunological profile is different according to the presence or absence of a previous pregnancy. Fetal immunological rejection could be involved in the pathogenesis of IUGR in primigravid women, but in multigravid women there were no differences between women with IUGR and those with normal fetal growth.     

Amniotic fluid volumes and concentrations of C-peptide in diabetic pregnancies

Summary. Amniotic fluid (AF) volumes were determined by sodium paminohippurate (PAH) diloution in a consecutive series of 24 diabetic women at 34–35 weeks gestation. AF and maternal venous blood samples were analysed for C-peptide immunoreactivity (CPR). When the patients were subgrouped according to the presence ( n =17) or absence ( n =8) of neonatal morbidity, AF volumes (1340±236 ml vs 807±130 ml; mean ±SEM), AF concentrations of CPR (l.38±0.54 nmol/1 vs 0.61±0.14 nmol/1) and maternal blood glucose levels (5.3±0.2 mmol/1 vs 4.8±0.3 mmol/1) during the last trimester of pregnancy were not different. The total content of CPR was significantly (P<0.05) greater in pregnancies with neonatal complications (1.25±0.31 nmol) compared with that in pregnancies without neonatal complications (0.54±0.18 nmol). AF volumes were significantly (P<0.02) larger in pregnancies where feeding problems occurred (1546±307 ml, n =9) compared with that in pregnancies without such problems (957±188 ml, n =16). These findings indicate an impact of fetal hyperinsulinism on the functional maturation of the fetus. When the patients were subgrouped according to the presence or absence of detectable maternal plasma CPR, i.e. >0.05 nmol/1, and to insulin dependent and gestational diabetes no differences of AF volumes, AF concentrations of CPR or total AF contents of CPR were found.     

Fetal pancreatic function in infants of diabetic and rhesus-isoimmunized women

OBJECTIVE: To measure insulin and glucagon concentrations in amniotic fluid (AF) collected near term in basal conditions and after an arginine test in diabetic, rhesus-isoimmunized, and control pregnant women. METHODS: At baseline, AF was collected from 44 diabetic, 32 rhesus-isoimmunized, and 27 control pregnant women in late pregnancy. Fifty-two diabetic, six rhesus-isoimmunized, and nine control pregnant women had amniocentesis 2 hours after arginine infusion (30 g intravenous/30 minutes) at 33-36 weeks. RESULTS: Baseline AF glucose concentrations were significantly greater in diabetic women than the other conditions, and they related to the gestational age in the women with hemolytic disease of the newborn. Insulin and glucagon AF content of isoimmunized pregnancies overlapped controls, whereas insulin and insulin/glucagon molar ratios were significantly higher, and glucagon values lower, in diabetic pregnancies compared with isoimmunized and control pregnancies. In isoimmunized pregnancies, the AF concentrations of glucose, insulin, and glucagon were correlated with gestational age (less than 34, 34 weeks or more). The samples collected after arginine infusion, compared with those collected at baseline, showed significantly greater insulin and insulin/glucagon molar ratio values in diabetic (28 +/- 5 versus 11 +/- 1 microU/mL, P = .001; 29.4 +/- 1.7 versus 12.0 +/- 2.8, P = .001) and in Rh pregnant women (18 +/- 6 versus 7.7 +/- 0.7 microU/mL, P = .001; 30 +/- 9 versus 3.4 +/- 0.4 I/G, P = .001), whereas no significant difference was observed in the controls. CONCLUSION: Basal islet hormone concentrations in AF are modified by maternal diabetes and further influenced by arginine administration. Arginine produces an AF response that is similar in pregnancies complicated by diabetes mellitus and rhesus-isoimmunization, despite different (hyperglycemia and euglycemia) maternal blood glucose levels.     

妊娠期糖尿病孕妇血清肿瘤坏死因子α水平变化与胰岛素抵抗关系的研究

目的　探讨妊娠期糖尿病孕妇血清肿瘤坏死因子α(TNF α)水平变化与胰岛素抵抗的关系。方法　采用酶联免疫吸附试验测定 4 2例妊娠期糖尿病孕妇 (GDM组 )、4 0例正常妊娠晚期孕妇 (正常妊娠组 )空腹血清TNF α水平 ;同时测定两组孕妇空腹血糖、C肽、胰岛素、糖化血红蛋白(HbA1c)水平。并且根据公式计算两组孕妇的胰岛素敏感指数 (ISI) ,以评价胰岛素抵抗程度。结果(1)GDM组孕妇空腹血清TNF α水平为 (5 2± 1 6 )ng/L ,正常妊娠组孕妇为 (4 5± 0 5 )ng/L ,两组比较 ,差异有极显著性 (P <0 0 1) ;GDM组孕妇ISI为 - 4 3± 0 4 ,正常妊娠组为 - 3 8± 0 3,两组比较 ,差异有极显著性 (P <0 0 1)。 (2 )GDM组孕妇空腹血糖、胰岛素、C肽水平分别为 (5 5± 0 7)mmol/L、(13 4± 3 8)mU/L、(1 6± 0 4 )nmol/L ,正常妊娠组孕妇空腹血糖、胰岛素、C肽水平分别为(4 9± 0 4 )mmol/L、(9 3± 2 5 )mU/L、(1 2± 0 3)nmol,两组比较 ,差异有极显著性 (P <0 0 1) ;GDM组孕妇HbA1c为 (5 6± 0 5 ) % ,正常妊娠组孕妇为 (5 3± 0 5 ) % ,两组比较 ,差异有显著性(P <0 0 5 )。 (3)GDM组孕妇空腹血清TNF α水平与ISI呈显著负相关 (r=- 0 70 3,P <0 0 1) ,分别与空腹血糖、C肽、HbA1c呈显著正相关 (r     

Maternal serum total cortisol levels in normal and pathologic pregnancies

The effect of pregnancy on maternal serum total cortisol (MSFT) was studied systematically in the course of 90 normal pregnancies (n = 204). Moreover, the evaluation of MSFT determinations in abnormal pregnancies, intrauterine growth retardation (IUGR) and obstetrical complications, premature rupture of the membranes (PROM), premature delivery (PD), and full term pregnancies with post maturity syndrome (PMS) were also investigated. MSFT was measured by an enzyme immunoassay. Gradual increase in MSFT was found from the 6th week of pregnancy to the 40th week of pregnancy and a sharp rise was noted during the last 2 weeks before the onset of labor (P less than 0.002). In IUGR, MSFT was significantly lower (P less than 0.001). In the cases of PROM and PD, MSFT was highly elevated (P less than 0.0001), independently of the gestational age. In pregnancies with well documented PMS, MSFT was much lower than in normal full term pregnancies with even a downward trend in serial determinations (P less than 0.0001).     

Glucose, insulin, HGH and IGF-I levels in maternal serum, amniotic fluid and umbilical venous serum: a comparison between late normal pregnancy and pregnancies complicated with diabetes and fetal growth retardation.

Fetal growth and development is dependent upon various growth factors such as glucose, insulin, HGH and IGF-I. These growth factors were measured in maternal serum (MS), amniotic fluid (AF) and umbilical venous serum (UV) in late gestation in normal, insulin dependent diabetic pregnancies (IDDM) and in pregnancies complicated with intrauterine growth retardation (IUGR). The UV glucose values of 1.9 +/- 0.9 mmol/L and UV insulin values of 8.0 +/- 1.8 mU/L were the lowest in IUGR pregnancies, and the highest were in UV serum from IDDM pregnancies, and the difference was statistically significant for this two groups. IGF-I values in UV indicated that there was significant difference in IGF-I concentrations when both, IUGR and IDDM groups were compared to the controls. There was a parallel shift in AF and MS glucose and insulin concentration as birthweight increased. The highest IGF-I values of 7.2 +/- 9.6 mumol/L in AF and MS were found in pregnancies with infants whose birthweight was 3500 grams and greater. Infants from pregnancies complicated with IUGR and IGF-I low values of 0.6 +/- 1.2 mumol/L in AF. HGH concentrations of 15.6 +/- 9.4 micrograms/L in UV were observed in IDDM pregnancies and significantly lower than the values in IUGR and normal pregnancies. HGH umbilical venous values decreased with duration of pregnancy and with increase in fetal size. The high HGH concentrations in the fetus and its dramatic fall after parturition, and the obtained negative correlation between HGH and IGF-I in umbilical vein may exhibit the maturation of the hypothalamic-growth hormone-IGF-I axis. It seems likely that changes in maternal serum, umbilical venous and amniotic fluid insulin-like growth factor I influence birthweight in normal and IUGR infants and in those of diabetic mothers.     

Perinatal outcome in growth retarded pregnancies dated by ultrasound

To analyse the incidence of fetal growth retardation and its impact on perinatal mortality and neonatal morbidity, pregnancies complicated by intra-uterine growth retardation (IUGR) were compared with matched non-IUGR pregnancies. The IUGR group included all infants born in the city of Malm? during the study period and having a birthweight of 2 standard deviations or more below the mean birthweight for gestational age. The gestational age of all pregnancies was assessed with ultrasound in the first half of pregnancy. The IUGR fetuses were more vulnerable during delivery, and emergency cesarean section due to imminent fetal asphyxia was performed more frequently, but Apgar scores were similar in both groups. The frequency of respiratory disorders was lower in the IUGR group than in the non-IUGR group when corticosteroid-treated pregnancies were excluded. The IUGR group required slightly longer care on the neonatal ward than the non-IUGR group, but not more intervention. The IUGR group as a whole had an unexpectedly low neonatal complication rate, such complications as did occur being related to preterm birth rather than to growth retardation.     

Endocrine Pancreatic Function in Fetuses of Gestational Diabetic and Nondiabetic Mothers

C-peptide, insulin, and glucagon levels were measured in the cord blood of 112 nondiabetics controls and 63 diabetic mothers. The cord blood levels of insulin and C-peptide were significantly higher in the diabetic compared to the control group. In the control group, C-peptide levels were positively correlated with fetal birthweight. In the diabetic group, there was a positive correlation between birth-weight and both C-peptide and insulin levels. Neonates were stratified into six categories of birthweight centiles. In the diabetic group, the insulin level was significantly higher than in the control group at all categories of birthweight centiles. Also, the C-peptide level was higher in the diabetic than in the control group, except at the >25 and ≥10 categories of birthweight centile. Glucagon levels were significantly higher among controls, at all categories of birthweight centiles, except in fetuses below the 10th centile of birth weight. The insulin/C-peptide ratio, a ratio that reflects hepatic insulin metabolism, was higher in the control than in the diabetic group. The results of the present study suggest that, even in the absence of macrosomia, fetuses of diabetic mothers are exposed to variable degrees of metabolic stress/adaptation, i.e., hyperinsulinaemia, increased hepatic insulin uptake, and a decrease in glucagon secretion. The long-term consequences of these changes may turn out to be more significant than its possible short-term effects on fetal growth and weight at birth.     

Complication of insulin-dependent diabetic pregnancies by preeclampsia and/or chronic hypertension: analysis of outcome

The significance of hypertensive complications of insulin-dependent diabetic pregnancies (IDDP) has not been well examined since the early reports of Pedersen, which demonstrated an increased risk of neonatal death in women with pregnancy induced hypertension (PIH). To assess the effect of both PIH and chronic hypertension (CH) on outcome of IDDP managed using contemporary obstetrical and diabetic management, we reviewed the records of all 199 IDDP delivered at our institution over a 7-year period. Patients were classified as having PIH (Group 1, n = 37), CH (Group 2, n = 18) or both (Group 3, n = 4) on the basis of standard clinical criteria. All other IDDP were placed in the control group (Group 4, n = 140). Comparing all groups, significant differences were found for maternal age (P less than .0001) and distribution among White's Classes (P less than .0001). There was no significant difference in estimated gestational age (EGA) at delivery, birthweight, Apgar scores, hypoglycemia, hyperbilirubinemia, or congenital anomalies. Intrauterine fetal death (IUFD) was no more common in Groups 1, 2 or 3 than in Group 4; however, IDDP with CH were significantly more likely to have had previous stillbirths than IDDP with PIH (P = .011) or control IDDP (P = .017). Contrary to common clinical belief, the "stress" of CH and PIH did not offer protection to the newborn in the development of RDS or HMD. In fact, Group 3 infants had a higher rate of HMD than control infants (P = .024).(ABSTRACT TRUNCATED AT 250 WORDS)     

Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse

OBJECTIVE: To determine the obstetric and perinatal outcomes of women using illicit drugs during pregnancy by substance group. METHOD: A retrospective audit of obstetric and perinatal outcomes in women who used opiates or amphetamines during their pregnancy and delivered at King Edward Memorial Hospital (KEMH), Perth, Australia between December 1997 and April 2000 was performed. Maternal, fetal and neonatal parameters were assessed. These were compared with obstetric and perinatal data recorded by the Health Department of Western Australia (HDWA) for the 25,291 deliveries of 25,677 infants in 1998. RESULTS: Between December 1997 and April 2000 91 opiate-using and 50 amphetamine-using women were identified and included in the analysis. Both groups of drug-using women were younger (opiates P = 0.001, amphetamines P = 0.001) than the general population. There was a higher incidence of aboriginality (P = 0.001) in the amphetamine group. In the opiate-using group multiparity (P = 0.0001) and anaemia (P = 0.0001) were higher. Illicit drug-using women had a higher incidence of hepatitis C (opiates P = 0.001, amphetamines P = 0.003), and a greater need for pharmacological analgesia for labour and delivery (opiates P = 0.007, amphetamines P = 0.042). Their infants were significantly more likely to deliver at less than 37 weeks' gestation (opiates P = 0.0001, amphetamines P = 0.001), to have a birthweight of less than 2.5 kg (P = 0.0001), be small for gestational age and require admission to the special care nursery (P = 0.0001). Infants born to women in the amphetamine group were more likely to have an Apgar score < 7 (P = 0.0001) recorded. Infants of women in the opiate group required more resuscitation (P = 0.05). CONCLUSION: Women who use illicit drugs are more likely to experience adverse obstetric and perinatal outcomes than women in the general population. Differences are seen depending on the type of illicit drug used. These findings need to be replicated in a larger prospective cohort to highlight management requirements of these women and their infants. Further information is required about the effects of amphetamines in pregnancy.     

Cord blood cortisol level is lower in growth-restricted newborns

AIM: To establish the difference in plasma cortisol concentrations between newborns with intrauterine growth-restricted (IUGR) and appropriate for gestational age (AGA) birthweights. SUBJECTS AND METHODS: We measured plasma cortisol concentrations in the umbilical venous cord blood of 68 IUGR newborns and 71 AGA birthweight newborns. All newborns were delivered in term, vaginally, in the morning, within 8 hours and had APGAR scores greater or equal to eight. RESULTS: There was no significant difference between compared groups according to maternal age, parity, gestational age and neonatal gender. Neonatal plasma cortisol levels were significantly lower in the IUGR (median: 312.3 mmol/L, min-max: 158.9-588.1 mmol/L) compared to the AGA group (median: 458.7 mmol/L, min-max: 314.5-718.5 mmol/L) (Mann-Whitney U-test; P<0000). The probability of having a cortisol plasma level greater than or equal to 458.7 mmol/L for IUGR newborns was only 1:12, and to have cortisol plasma level less than or equal to 312.3 mmol/L for AGA newborns was much lower (0:34). In the range of plasma cortisol level between 312.3 mmol/L and 458.7 mmol/L, no statistically significant difference in the plasma cortisol level between IUGR and AGA newborns was found. CONCLUSIONS: Neonatal plasma cortisol level is lower in the IUGR compared to the AGA group. Our results suggest that endocrine relationships seem to be lost in a specific group of the IUGR newborns. Although we usually tend to simplify the problem and declare only one cause, this time it is impossible. It is probable that the cause is hidden in small and insufficient placenta with deranged auto-regulation of placental 11beta-HSD-2 mechanism.     

Serum cystatin C in pregnancies with normal and restricted fetal growth

The objective of this study was to investigate circulating levels of cystatin C (an important endogenous marker of renal function) in mothers, fetuses, and neonates from intrauterine growth-restricted (IUGR; characterized by impaired nephrogenesis) and appropriate-for-gestational-age (AGA) pregnancies. Serum cystatin C levels were measured by enzyme immunoassay in 40 parturients and their 20 IUGR (or= 0.376 and P 相似文献   

Fetal beta cell function in diabetic pregnancy. Amniotic fluid concentrations of proinsulin, insulin, and C-peptide during the last trimester of pregnancy

Proinsulin, insulin C-peptide, insulin-binding antibody, and glucose concentrations were measured in amniotic fluid samples from 43 insulin-treated diabetic patients and 17 nondiabetic control patients between the thirty-six and thirty-ninth weeks of gestation. Insulin-binding antibodies in amniotic fluid were present in only three diabetic patients, although antibodies in maternal serum were found in 22 of the diabetic subjects. In the diabetic group, maternal serum insulin-binding antibodies were statistically unrelated to levels of C-peptide in amniotic fluid. The mean amniotic fluid concentrations of proinsulin (0.07 nmole/L), insulin (0.08 nmole/L), C-peptide (1.17 nmoles/L), and glucose (2.09 mmoles/L) were markedly elevated (p less than 0.001) in diabetic patients, as compared to nondiabetic control patients, thus suggesting exaggerated fetal beta cell function. C-peptide was correlated to both insulin (r = 0.69) and proinsulin (r = 0.35) in the diabetic group only. Infant birth weight and amniotic fluid C-peptide was significantly correlated in both the control group (r = 0.54) and the diabetic group (r = 0.38). Diabetic pregnancies associated with neonatal morbidity (n = 25) had significantly higher mean amniotic fluid concentrations of both insulin and C-peptide than did pregnancies without neonatal morbidity (n = 18). The amniotic fluid values of C-peptide and insulin in these latter two subgroups were overlapping and, therefore, could not serve to predict neonatal outcome in the individual case.     

Lupus anticoagulant in pre-eclampsia and intra-uterine growth retardation.

In a prospective study we proposed to identify the relationship between the level of lupus anticoagulant activity in pre-eclampsia and in growth retardation among 88 pregnant women. In 23 women suffering from severe pre-eclampsia (PET), and 22 women with fetal growth retardation, the mean anticardiolipin binding index was significantly higher than 43 controls (P less than 0.01 and P less than 0.005, respectively). The mean kaolin cephalin clotting time (KCCT) was significantly higher in patients with severe PET than in the control group (P less than 0.05). In intra-uterine growth retardation (IUGR), patients with 610-2452 g infants had significantly higher anticardiolipin binding index than those with 2500-3200 g infants (P less than 0.05). The Caesarean section rate was 46% in the patients with intra-uterine growth retardation (IUGR), 43% in the PET patients, and 2% in the control group.     

Alterations of maternal metabolism in normal and diabetic pregnancies: differences in insulin-dependent, non-insulin-dependent, and gestational diabetes

In normal and diabetic pregnancies, the placenta functions as a complex endocrine gland that modulates all classes of maternal nutrients to the fetus. The metabolic alterations of normal pregnancy are diabetogenic and associated with modest resistance to endogenous insulin. Pregnant women with carbohydrate intolerance represent three metabolically heterogeneous groups: type I (insulin-dependent), type II (non-insulin-dependent), and gestational diabetes. Patients with type I diabetes are at risk for ketosis and require replacement therapy because of a deficient production of insulin. They have decreased 24-hour, around-the-clock levels of C-peptide and glucagon, and lower nocturnal cortisol values and higher 24-hour prolactin levels than those of women with type II diabetes. Type II pregnant diabetic patients are not prone to ketosis and are more resistant to endogenous and exogenous insulin. They have higher fasting and meal-stimulated levels of C-peptide, accentuated fasting hypertriglyceridemia, and significantly lower high-density lipoprotein cholesterol levels than those of normal or type I women. In gestational diabetes, the metabolic stress of pregnancy evokes reversible hyperglycemia which may be associated with either a surfeit or a deficiency of insulin. These metabolic differences among diabetic pregnant women could have implications for placental structure and function that might influence fetal growth.